A multicenter phase 1 trial of tucatinib, trastuzumab, and capecitabine with stereotactic radiosurgery in patients with brain metastases from HER-2–positive breast cancer (TUTOR)
Latest Information Update: 05 Jul 2024
At a glance
- Drugs Capecitabine (Primary) ; Trastuzumab (Primary) ; Tucatinib (Primary)
- Indications Brain metastases; HER2 positive breast cancer
- Focus Adverse reactions
- Acronyms TUTOR
Most Recent Events
- 05 Jul 2024 New trial record